Completed PHASE4 INTERVENTIONAL 2-arm NCT02597543

Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction

Stress Cardiac MRI Using Regadenoson for Evaluation of Nonspecific Allograft Dysfunction

Sponsor: Astellas Pharma Inc

Conditions Acute Graft Rejection Chronic Graft Rejection Heart Transplant

Interventions Cardiac MRI Gadolinium Regadenoson

Updated 10 times since 2017 Last updated: Jul 24, 2017 Started: Nov 30, 2015 Primary completion: Jun 30, 2016 Completion: Jun 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02597543, this PHASE4 trial focuses on Acute Graft Rejection and Chronic Graft Rejection and remains completed. Sponsored by Astellas Pharma Inc, it has been updated 10 times since 2015, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4
Jan 2021 — Dec 2022 [monthly]

Completed PHASE4

▶ Show 5 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Sep 2017 — Jun 2018 [monthly]

Completed PHASE4
Jun 2017 — Sep 2017 [monthly]

Completed PHASE4

Status: Not Yet Recruiting → Completed
Feb 2017 — Jun 2017 [monthly]

Not Yet Recruiting PHASE4
Jan 2017 — Feb 2017 [monthly]

Not Yet Recruiting PHASE4

First recorded

Nov 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma Inc
Paul Kim

Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• La Jolla, United States